LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Harvard Bioscience Inc

Închisă

SectorSănătate

0.73 -3.95

Rezumat

Modificarea prețului

24h

Curent

Minim

0.72

Maxim

0.76

Indicatori cheie

By Trading Economics

Venit

1.1M

-1.2M

Vânzări

141K

21M

Marjă de profit

-5.978

Angajați

330

EBITDA

1M

1.2M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+163.16% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

8.2M

34M

Deschiderea anterioară

4.68

Închiderea anterioară

0.73

Sentimentul știrilor

By Acuity

26%

74%

84 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Harvard Bioscience Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 dec. 2025, 22:02 UTC

Câștiguri

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 dec. 2025, 21:46 UTC

Câștiguri

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 dec. 2025, 23:52 UTC

Achiziții, Fuziuni, Preluări

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 dec. 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 dec. 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 dec. 2025, 23:20 UTC

Câștiguri

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 dec. 2025, 23:15 UTC

Câștiguri

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 dec. 2025, 22:59 UTC

Market Talk
Câștiguri
Achiziții, Fuziuni, Preluări

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 dec. 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 dec. 2025, 22:40 UTC

Câștiguri

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dec. 2025, 22:06 UTC

Achiziții, Fuziuni, Preluări

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dec. 2025, 22:06 UTC

Câștiguri

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dec. 2025, 22:02 UTC

Câștiguri

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dec. 2025, 22:00 UTC

Câștiguri

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 dec. 2025, 21:53 UTC

Câștiguri

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dec. 2025, 21:50 UTC

Achiziții, Fuziuni, Preluări

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 dec. 2025, 21:50 UTC

Market Talk
Câștiguri
Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

10 dec. 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 dec. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10 dec. 2025, 21:45 UTC

Achiziții, Fuziuni, Preluări

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dec. 2025, 21:33 UTC

Câștiguri

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 dec. 2025, 21:32 UTC

Câștiguri

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dec. 2025, 21:28 UTC

Achiziții, Fuziuni, Preluări

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 dec. 2025, 21:25 UTC

Câștiguri

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dec. 2025, 21:18 UTC

Achiziții, Fuziuni, Preluări

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 dec. 2025, 21:16 UTC

Câștiguri

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 dec. 2025, 21:15 UTC

Achiziții, Fuziuni, Preluări

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 dec. 2025, 21:15 UTC

Câștiguri

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 dec. 2025, 21:14 UTC

Câștiguri

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 dec. 2025, 21:14 UTC

Câștiguri

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Comparație

Modificare preț

Harvard Bioscience Inc Așteptări

Obiectiv de preț

By TipRanks

163.16% sus

Prognoză pe 12 luni

Medie 2 USD  163.16%

Maxim 2 USD

Minim 2 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHarvard Bioscience Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

1

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.3 / 0.3401Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

No Evidence

Termen lung

No Evidence

Sentiment

By Acuity

84 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat